Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial

Authors: Stein Gold, Linda, Adam, David N., Albrecht, Lorne, Alonso-Llamazares, Javier, Ferris, Laura K., Gooderham, Melinda J., Hong, H. Chih-ho, Kempers, Steven E., Kircik, Leon H., Lebwohl, Mark, Loo, Wei Jing, Nahm, Walter K., Papp, Kim A., Stewart, Daniel, Toth, Darryl P., Zirwas, Matthew, Krupa, David, Snyder, Scott, Burnett, Patrick, Higham, Robert, Berk, David R.

Source: In Journal of the American Academy of Dermatology August 2024 91(2):273-280

Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial

Authors: Blauvelt, Andrew, Draelos, Zoe D., Stein Gold, Linda, Alonso-Llamazares, Javier, Bhatia, Neal, DuBois, Janet, Forman, Seth B., Gooderham, Melinda, Green, Lawrence, Guenthner, Scott T., Hebert, Adelaide A., Lain, Edward, Moore, Angela Y., Papp, Kim A., Zirwas, Matthew, Kato, Saori, Snyder, Scott, Krupa, David, Burnett, Patrick, Berk, David R., Chu, David H.

Source: In Journal of the American Academy of Dermatology May 2024 90(5):986-993

Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older

Authors: Buchwald, Ulrike K., Andrews, Charles P., Ervin, John, Peterson, James T., Tamms, Gretchen M., Krupa, David, Ajiboye, Patrick, Roalfe, Lucy, Krick, Andrea L., Sterling, Tina M., Wang, Meihua, Martin, Jason C., Stek, Jon E., Kohn, Melvin A., Folaranmi, Temitope, Abeygunawardana, Chitrananda, Hartzel, Jonathan, Musey, Luwy K.

Source: Human vaccines & immunotherapeutics. 17(8):2678-2690

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100130268068.0x000001&indx=1&recIds=ETOCvdc_100130268068.0x000001

Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.

Authors: Simpson, Eric L., Eichenfield, Lawrence F., Alonso-Llamazares, Javier, Draelos, Zoe D., Ferris, Laura K., Forman, Seth B., Gooderham, Melinda, Gonzalez, Mercedes E., Hebert, Adelaide A., Kircik, Leon H., Lomaga, Mark, Moore, Angela, Papp, Kim A., Prajapati, Vimal H., Hanna, Diane, Snyder, Scott, Krupa, David, Burnett, Patrick, Almaraz, Erin, Higham, Robert C.

Source: JAMA Dermatology; Nov2024, Vol. 160 Issue 11, p1161-1170, 10p

Layer-Specific Somatosensory Cortical Activation during Active Tactile Discrimination

Authors: Krupa, David J., Wiest, Michael C., Shuler, Marshall G., Laubach, Mark

Source: Science, 2004 Jun . 304(5679), 1989-1992.

Access URL: https://www.jstor.org/stable/3837211

Immediate Thalamic Sensory Plasticity Depends on Corticothalamic Feedback

Authors: Krupa, David J., Ghazanfar, Asif A.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1999 Jul . 96(14), 8200-8205.

Access URL: https://www.jstor.org/stable/48451

Inhibitory Cerebello-Olivary Projections and Blocking Effect in Classical Conditioning

Authors: Kim, Jeansok J., Krupa, David J., Thompson, Richard F.

Source: Science, 1998 Jan . 279(5350), 570-573.

Access URL: https://www.jstor.org/stable/2894047

Pooled Efficacy, Patient-reported Outcomes, and Safety of Roflumilast Cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 Phase 3 Trials of Patients with Atopic Dermatitis and Prior Inadequate Response, Intolerance, and/or Contraindications for Topical Corticosteroids

Authors: Simpson, Eric ¹, Eichenfield, Lawrence ², Geng, Bob ², Gonzalez, Mercedes ³, Hebert, Adelaide ⁴, Prajapati, Vimal ⁵, Gooderham, Melinda ⁶, Krupa, David ⁷, Chu, David ⁷, Hanna, Diane ⁷, Higham, Robert ⁷, Berk, David ⁷, Boguniewicz, Mark ⁸

Source: In The Journal of Allergy and Clinical Immunology February 2025 155(2) Supplement:AB199-AB199

Cerebellum and Learning: A Complex Problem

Authors: Hesslow, Germund, Yeo, Christopher, Kim, Jeansok J., Krupa, David J., Thompson, Richard F.

Source: Science, 1998 Jun . 280(5371), 1817-1819.

Access URL: https://www.jstor.org/stable/2895567

Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.

Authors: Kircik, Leon H, Alonso-Llamazares, Javier, Bhatia, Neal, Bukhalo, Michael, Devani, Alim R, Draelos, Zoe D, DuBois, Janet, Gooderham, Melinda J, Kempers, Steven E, Lain, Edward, Lee, Mark, Moore, Angela, Murrell, Dedee F, Papp, Kim A, Pariser, David M, Sinclair, Rodney, Zirwas, Matthew, Burnett, Patrick, Higham, Robert C, Krupa, David

Source: British Journal of Dermatology; Oct2023, Vol. 189 Issue 4, p392-399, 8p

Subject Terms: SCALP, PSORIASIS, FOAM, ITCHING, TEENAGERS

53894 Roflumilast foam 0.3% once daily in patients with seborrheic dermatitis: Improvement in patient reported outcomes and pruritus from a phase 3 trial (STRATUM)

Authors: Bhatia, Neal, Cook-Bolden, Fran, DuBois, Janet, Ferris, Laura, Gold, Linda Stein, Turchin, Irina, Zirwas, Matthew, Krupa, David, Burnett, Patrick, Berk, David R., Chu, David H.

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB304-AB304

53863 Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 clinical trials of adults and children with atopic dermatitis

Authors: Simpson, Eric, Boguniewicz, Mark, Eichenfield, Lawrence, Gonzales, Mercedes E., Hebert, Adelaide A., Prajapati, Vimal H., Gooderham, Melinda, Krupa, David, Chu, David H., Higham, Robert C., Berk, David R.

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB281-AB281

53817 Patient-reported outcomes with roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial

Authors: Gooderham, Melinda, Bagel, Jerry, Forman, Seth B., Kircik, Leon, Wiseman, Marni, Lockshin, Benjamin, Soung, Jennifer, Krupa, David, Kato, Saori, Berk, David R., Chu, David H.

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB276-AB276

53025 Roflumilast cream 0.3% in patients with psoriasis: Improvement in patient reported outcomes and pruritus from two pooled phase 3 trials (DERMIS-1/DERMIS-2)

Authors: Lebwohl, Mark, Hong, Chih-Ho, Kircik, Leon, Soung, Jennifer, Gooderham, Melinda, Moore, Angela, Del Rosso, James, Turchin, Irina, Krupa, David, Higham, Robert, Berk, David

Source: In Journal of the American Academy of Dermatology September 2024 91(3) Supplement:AB82-AB82

A Balancing Act: Ethnography, Subsistence, and Alaska Parks

Authors: Krupa, David J.

Source: The George Wright Forum, 2009 Jan 01. 26(3), 101-109.

Access URL: https://www.jstor.org/stable/43598124

Wasting Away

Authors: Borgatti, Douglas R., Brooks, Jane A., Carney, Kevin B., Nowak, Mickey J., Krupa, David P., Kruzel, Joseph P., Maheux, Leo D., Tower, Susan A.

Source: Water Environment & Technology, 2001 Feb 01. 13(2), 54-59.

Access URL: https://www.jstor.org/stable/24668617

Inactivation of the Superior Cerebellar Peduncle Blocks Expression but not Acquisition of the Rabbit's Classically Conditioned Eye-Blink Response

Authors: Krupa, David J., Thompson, Richard F.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1995 May . 92(11), 5097-5101.

Access URL: https://www.jstor.org/stable/2367678

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

Authors: Zirwas, Matthew J., Draelos, Zoe D., DuBois, Janet, Kircik, Leon H., Moore, Angela Y., Stein Gold, Linda, Alonso-Llamazares, Javier, Bukhalo, Michael, Bruce, Suzanne, Eads, Kimmie, Green, Lawrence J., Guenthner, Scott T., Ferris, Laura K., Forman, Seth B., Kempers, Steven E., Lain, Edward, Lynde, Charles W., Pariser, David M., Toth, Darryl P., Yamauchi, Paul S., Higham, Robert C., Krupa, David, Burnett, Patrick, Berk, David R.

Source: JAMA Dermatology; June 2023, Vol. 159 Issue: 6 p613-620, 8p

Miniaturized high-density multichannel electrode array for long-term neuronal recordings

42828 Efficacy and safety of roflumilast cream 0.3% in patients with chronic plaque psoriasis: pooled PASI and PASI-HD results from the DERMIS-1 and DERMIS-2 Phase 3 Trials

Authors: Papp, Kim, Lebwohl, Mark, Hong, H. Chih-ho, Kircik, Leon, Pariser, David, Strober, Bruce, Krueger, Gerald, Krupa, David, Burnett, Patrick, Berk, David, Higham, Robert

Source: In Journal of the American Academy of Dermatology September 2023 89(3) Supplement:AB156-AB156